Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Barriers to Clinical Trial Implementation Among Community Care Centers.
Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia NJ, Zengin ZB, Meza L, Chawla N, Castro DV, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer RA, Boehmer L, Pal S, Chehrazi-Raffle A. Ebrahimi H, et al. Among authors: chehrazi raffle a. JAMA Netw Open. 2024 Apr 1;7(4):e248739. doi: 10.1001/jamanetworkopen.2024.8739. JAMA Netw Open. 2024. PMID: 38683608 Free PMC article.
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations.
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan BL, Pal SK. Gebrael G, et al. Among authors: chehrazi raffle a. Eur Urol Focus. 2024 Apr 4:S2405-4569(24)00050-6. doi: 10.1016/j.euf.2024.03.006. Online ahead of print. Eur Urol Focus. 2024. PMID: 38580524
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Alcantara MB, Tang WS, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal SK, Kortylewski M. Alcantara MB, et al. Among authors: chehrazi raffle a. Front Immunol. 2024 Jan 8;14:1274781. doi: 10.3389/fimmu.2023.1274781. eCollection 2023. Front Immunol. 2024. PMID: 38259453 Free PMC article.
Boosting CAR T cells with anti-tumor mRNA vaccines.
Chehrazi-Raffle A, Budde LE, Pal SK. Chehrazi-Raffle A, et al. Nat Med. 2023 Nov;29(11):2711-2712. doi: 10.1038/s41591-023-02623-x. Nat Med. 2023. PMID: 37932550 No abstract available.
Reply by Authors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: chehrazi raffle a. Urol Pract. 2023 Oct 30:101097UPJ000000000000047102. doi: 10.1097/UPJ.0000000000000471.02. Online ahead of print. Urol Pract. 2023. PMID: 37903752 No abstract available.
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Mathew Thomas V, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: chehrazi raffle a. Urol Pract. 2024 Jan;11(1):32-35. doi: 10.1097/UPJ.0000000000000471. Epub 2023 Oct 30. Urol Pract. 2024. PMID: 37903742
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
Bergerot CD, Philip EJ, Malhotra J, Bergerot PG, Castro DV, Govindarajan A, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin ZB, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Bergerot CD, et al. Among authors: chehrazi raffle a. J Genet Couns. 2023 Sep 12. doi: 10.1002/jgc4.1786. Online ahead of print. J Genet Couns. 2023. PMID: 37697864
Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A, Salgia NJ, Li H, Castro DV, Mirzapoiazova T, Armstrong B, Zhao D, Mercier BD, Dizman N, Chawla N, Zengin Z, Meza L, Tripathi N, Sayegh N, Chehrazi-Raffle A, Tripathi A, Pal SK. Govindarajan A, et al. Among authors: chehrazi raffle a. Front Immunol. 2023 Aug 11;14:1182581. doi: 10.3389/fimmu.2023.1182581. eCollection 2023. Front Immunol. 2023. PMID: 37638025 Free PMC article.
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.
Castro DV, Prajapati SR, Feng MI, Chan EH, Lee KO, Paul T, Sehgal I, Patel J, Li X, Zengin ZB, Ebrahimi H, Govindarajan A, Meza L, Mercier BD, Chawla NS, Dizman N, Philip EJ, Hsu J, Bergerot CD, Chehrazi-Raffle A, Rock A, Liu S, Tripathi A, Dorff TB, Pal SK. Castro DV, et al. Among authors: chehrazi raffle a. BJU Int. 2024 Mar;133(3):297-304. doi: 10.1111/bju.16148. Epub 2023 Sep 1. BJU Int. 2024. PMID: 37548533
37 results